Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
denovoSkin versus split-thickness skin graft for deep partial and full-thickness burns
NL-OMON58899Phase 3Recruiting
- Sponsor
- CUTISS
- Start
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of denovoSkin in burn injury and deep partial-thickness burn (2 arms), sponsored by CUTISS. Primary endpoint: Composite primary endpoint. Started Dec 2024; status: recruiting.
02
Drugs
denovoSkin
03
Conditions
burn injurydeep partial-thickness burn
Beyond the preview
Go deeper on NL-OMON58899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58899.